Dynavax to Discuss TOLAMBATM
Chamber Data; Update 2008 Outlook in Webcast This Morning
BERKELEY, Calif. (Business Wire EON) May 16, 2008 --
Dynavax Technologies (Nasdaq:DVAX) will webcast this morning a
discussion of the TOLAMBA Chamber study data and provide an updated
financial outlook for 2008.
A live webcast will begin at 8:45 a.m. EDT (5:45 a.m. PDT). The webcast
can be accessed from Dynavax’s website at www.dynavax.com
under the Investors / Events tab or by using the link http://investors.dynavax.com/events.cfm.
An archived version of the webcast will be available on the company’s
website beginning at 11:45 a.m. EDT (8:45 a.m. PDT) through May 30, 2008.
ABOUT DYNAVAX
Dynavax Technologies Corporation discovers, develops, and intends to
commercialize innovative TLR9 agonist-based products to treat and
prevent infectious diseases, allergies, cancer, and chronic inflammatory
diseases using versatile, proprietary approaches that alter immune
system responses in highly specific ways. Our TLR9 agonists are based on
immunostimulatory sequences, or ISS, which are short DNA sequences that
enhance the ability of the immune system to fight disease and control
chronic inflammation. Our clinical product candidates include: HEPLISAV™,
a hepatitis B vaccine partnered with Merck & Co., Inc.; a therapy for
metastatic colorectal cancer; and therapies for hepatitis B and C. Our
preclinical asthma and COPD program is partnered with AstraZeneca. The
NIH partially funds our preclinical work on a universal vaccine for
influenza. Symphony Dynamo Inc. (SDI) funds our colorectal cancer and
hepatitis C therapeutic programs. While NIH and SDI provide program
support, Dynavax has retained rights to seek strategic partners for
future development and commercialization. For more information, please
visit http://www.dynavax.com.
Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/RW1wdC1QaWdnLVByb2YtTWFnbi1DcmFzLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
